Marengo Therapeutics, Inc.
https://marengotx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Marengo Therapeutics, Inc.
Ipsens Onivyde Pancreatic Cancer Trial Survival Disappointment Dashes Sales Boost Hopes
The French firm unveiled data from its pancreatic cancer trial showing Onivyde plus chemotherapy improved median PFS by just over a month compared with current treatment of choice but failed to beat its overall survival benchmark.
Tech Transfer Roundup: MD Anderson, NCI Lead Cancer Alliances
MD Anderson and the US National Cancer Institute lead the way with a series of recent alliances, highlighted in this special edition of Tech Transfer Roundup focused on oncology.
Ipsen’s Onivyde Hits Bullseye In Pivotal First-Line Pancreatic Cancer Trial
The French firm’s Onivyde has succeeded as part of a combination regimen in chemotherapy-naïve pancreatic cancer patients, setting it up for a label expansion, but some experts are keen to see survival data in full before raising guidance.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice